Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 13/20 | 0.41 |
| ▸ | FNTB | P49356 | 13/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8498596 | 1.00 | FNTA (0.41) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8501177 | 0.98 | FNTA (0.41) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8487916 | 0.93 | FNTA (0.42) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8487917 | 0.93 | FNTA (0.42) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8493893 | 0.93 | FNTA (0.43) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8493898 | 0.93 | FNTA (0.43) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8495276 | 0.92 | FNTA (0.42) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8497333 | 0.90 | FNTA (0.41) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8493109 | 0.90 | FNTA (0.39) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8341670 | 0.89 | FNTA (0.42) | FNTAFNTBPGGT1BCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999012912-A1 | THIOUREA DERIVATIVES OR NON-TOXIC SALTS THEREOF FOR INHIBITNG RAS-TRANSFORMED CELL GROWTH | YUHAN CORPORATION (KR) | 1999-03-18 | — | — | WO | disclosed |